VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2011-2014

ABSTRACT

First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and immunogenic response to the investigational vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose. More... »

URL

https://clinicaltrials.gov/show/NCT01486329

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and immunogenic response to the investigational vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose.", 
    "endDate": "2014-12-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT01486329", 
    "keywords": [
      "dose escalation study", 
      "stage IV", 
      "Examine", 
      "tolerability", 
      "immune response", 
      "DNA vaccine", 
      "patient", 
      "VEGFR", 
      "vaccine", 
      "vascular endothelial growth factor receptor", 
      "Vascular Endothelial Growth Factor Receptor-2", 
      "maximum tolerated dose"
    ], 
    "name": "VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT01486329"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:24", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00011.json", 
    "startDate": "2011-12-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1471-2407-12-361", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044632467", 
          "https://doi.org/10.1186/1471-2407-12-361"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/neuonc/nov180", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059934994"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT01486329"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT01486329'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT01486329'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT01486329'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT01486329'


 

This table displays all metadata directly associated to this object as RDF triples.

36 TRIPLES      15 PREDICATES      28 URIs      21 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT01486329 schema:about anzsrc-for:3103
2 schema:description First-in-human phase I dose escalation study in patients with locally advanced, inoperable and stage IV pancreatic cancer to examine safety, tolerability, and immune response to the investigational VEGFR-2 DNA vaccine VXM01 to examine safety and tolerability, clinical and immunogenic response to the investigational vascular endothelial growth factor receptor 2 (VEGFR-2) DNA vaccine VXM01, and to define the maximum tolerated dose.
3 schema:endDate 2014-12-01T00:00:00Z
4 schema:keywords DNA vaccine
5 Examine
6 VEGFR
7 Vascular Endothelial Growth Factor Receptor-2
8 dose escalation study
9 immune response
10 maximum tolerated dose
11 patient
12 stage IV
13 tolerability
14 vaccine
15 vascular endothelial growth factor receptor
16 schema:name VXM01 Phase I Dose Escalation Study in Patients With Locally Advanced, Inoperable and Stage IV Pancreatic Cancer to Examine Safety, Tolerability, and Immune Response to the Investigational VEGFR-2 DNA Vaccine VXM01
17 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT01486329
18 schema:sdDatePublished 2019-03-07T15:24
19 schema:sdLicense https://scigraph.springernature.com/explorer/license/
20 schema:sdPublisher Nf1f22b64b0fe4e54bc49277bd4813266
21 schema:startDate 2011-12-01T00:00:00Z
22 schema:subjectOf sg:pub.10.1186/1471-2407-12-361
23 https://doi.org/10.1093/neuonc/nov180
24 schema:url https://clinicaltrials.gov/show/NCT01486329
25 sgo:license sg:explorer/license/
26 sgo:sdDataset clinical_trials
27 rdf:type schema:MedicalStudy
28 Nf1f22b64b0fe4e54bc49277bd4813266 schema:name Springer Nature - SN SciGraph project
29 rdf:type schema:Organization
30 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
31 rdf:type schema:DefinedTerm
32 sg:pub.10.1186/1471-2407-12-361 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044632467
33 https://doi.org/10.1186/1471-2407-12-361
34 rdf:type schema:CreativeWork
35 https://doi.org/10.1093/neuonc/nov180 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059934994
36 rdf:type schema:CreativeWork
 




Preview window. Press ESC to close (or click here)


...